Evidence map›Paper›PMID 27189755›Full record

ReviewNeurobiology of disease2017

Update of neurotrophic factors in neurobiology of addiction and future directions.

Maryna Koskela, Susanne Bäck, Vootele Võikar, Christopher T Richie, Andrii Domanskyi, Brandon K Harvey, Mikko Airavaara

Open access · greenAbstract readReview
In one paragraph

Review in Neurobiology of disease, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. A history of addiction through the six editions of Kandel'sFrontiers in behavioral neuroscience · 2026
    Review
  4. Article
  5. Article
  6. Review
  7. Substance Use and Addiction.Advances in neurobiology · 2024
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Nanoparticle delivery systems for substance use disorder.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2022
    Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Growth Factors and Alcohol Use Disorder.Cold Spring Harbor perspectives in medicine · 2020
    Review
  20. Regulation of GABAInternational journal of molecular sciences · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Maryna KoskelaInstitute of Biotechnology, P.O. Box 56, 00014, University of Helsinki, Finland.
Susanne BäckIntramural Research Program, National Institute on Drug Abuse, NIH, Baltimore, MD, USA.
Vootele VõikarNeuroscience Center, P.O. Box 56, 00014, University of Helsinki, Helsinki, Finland.
Christopher T RichieIntramural Research Program, National Institute on Drug Abuse, NIH, Baltimore, MD, USA.
Andrii DomanskyiInstitute of Biotechnology, P.O. Box 56, 00014, University of Helsinki, Finland.
Brandon K HarveyIntramural Research Program, National Institute on Drug Abuse, NIH, Baltimore, MD, USA.
Mikko AiravaaraInstitute of Biotechnology, P.O. Box 56, 00014, University of Helsinki, Finland. Electronic address: mikko.airavaara@helsinki.fi.
University of Helsinki · FINational Institute on Drug Abuse · US

Funding

Gene Delivery and AddictionZIADA000526 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI HARVEY, BRANDON · 2009 to 2022
$3.2M
Gene Therapy And NeurodegenerationZIADA000443 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI HARVEY, BRANDON · 2009 to 2020
$2.7M
Gene Therapy And NeuroprotectionZ01DA000443 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI HARVEY, BRANDON · 2001 to 2008
$1.3M
Gene Delivery and AddictionZ01DA000526 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI HARVEY, BRANDON · 2008 to 2008
$498k
Intramural NIH HHS Z01 DA000443Intramural NIH HHS Z01 DA000526
6 · The paper itself

Abstract

Drug addiction is a chronic brain disease and drugs of abuse cause long lasting neuroadaptations. Addiction is characterized by the loss of control over drug use despite harmful consequences, and high rates of relapse even after long periods of abstinence. Neurotrophic factors (NTFs) are well known for their actions on neuronal survival in the peripheral nervous system. Moreover, NTFs have been shown to be involved in synaptic plasticity in the brain. Brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF) are two of the most studied NTFs and both of them have been reported to increase craving when administered into the mesocorticolimbic dopaminergic system after drug self-administration. Here we review recent data on BDNF and GDNF functions in addiction-related behavior and discuss them in relation to previous findings. Finally, we give an insight into how new technologies could aid in further elucidating the role of these factors in drug addiction.

Indexed as

AnimalsHumansNerve Growth FactorsSubstance-Related DisordersNerve Growth Factors

Identifiers

PMID27189755
PMCPMC5108688
OpenAlexW2358640716

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.